Welcome to our dedicated page for Onconetix SEC filings (Ticker: ONCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Onconetix, Inc. filings document the regulatory record of a Nasdaq-listed biotechnology company focused on men's health and oncology diagnostics. Registration statements, amendments, proxy materials, and current reports describe securities offerings, preferred stock and warrant terms, common-stock structure, shareholder voting matters, and reverse-stock-split authorizations.
The company's SEC reports also disclose governance changes, board and executive appointments, material agreements, operating and financial results, clinical or regulatory matters, and risk factors related to its commercial-stage biotechnology business and Proclarix prostate cancer diagnostic.
Onconetix, Inc. filed a Form D for a Regulation D private offering reporting a $12,977,670 total offering, all of which has been sold with $0 remaining. The company identified its industry as Biotechnology, is organized in Delaware, and lists its principal office in Cincinnati, OH. The filing shows the offering relied on Rule 506(b) and reports the date of first sale as 2025-09-22. The issuer reports no revenues and selected the aggregate net asset value bracket indicating no net assets.
The offering included multiple security types — equity, debt, and options/warrants — and accepted investments from 11 investors with a stated minimum investment of $208,823. No sales commissions or finders' fees were paid, and the filing indicates $0 in proceeds used to pay officers, directors, or promoters (estimate). The Form D was signed by Karina Fedasz, Interim Chief Financial Officer, on 2025-10-07.
Onconetix, Inc. entered into a private investment in public equity (PIPE) financing with institutional investors, raising approximately $6.25 million through Series E convertible preferred stock and warrants. The company issued 7,813 shares of Series E preferred stock and Warrants to purchase 2,025,223 shares of common stock.
The Series E preferred stock has a Conversion Price of $3.8576 per share of common stock, subject to anti-dilution and variable-price adjustments, with a Floor Price of $0.7715. If certain Triggering Events occur, a Default Dividend of 15.0% per year accrues on the stated value and holders gain alternate conversion rights.
The Warrants are immediately exercisable at an initial exercise price of $3.8576 per share, include only downward price adjustments, and have a three-year term. Both the preferred shares and Warrants are subject to an ownership cap, generally limiting a holder’s beneficial ownership to 4.99%, adjustable up to 9.99% with notice.
Onconetix, Inc. filed a Form 8-K reporting several material corporate actions disclosed in press releases dated September 26, 2025. The filing references a PIPE Financing and Settlement Agreement and a separate press release announcing the Termination of Merger Agreement. It also lists transaction exhibits including a Certificate of Designations that authorizes Series D Preferred Stock, a Form of Warrant, and the PIPE Financing and Settlement Agreement as exhibits. The filing describes an Alternate Conversion Right that permits holders to convert Preferred Shares into Common Stock after certain triggering events and after the Stockholder Approval Date at specified alternate conversion prices. The document is signed by the company’s Interim Chief Executive Officer and Interim Chief Financial Officer.
Onconetix, Inc. filed a Form 8-K reporting several material corporate actions disclosed in press releases dated September 26, 2025. The filing references a PIPE Financing and Settlement Agreement and a separate press release announcing the Termination of Merger Agreement. It also lists transaction exhibits including a Certificate of Designations that authorizes Series D Preferred Stock, a Form of Warrant, and the PIPE Financing and Settlement Agreement as exhibits. The filing describes an Alternate Conversion Right that permits holders to convert Preferred Shares into Common Stock after certain triggering events and after the Stockholder Approval Date at specified alternate conversion prices. The document is signed by the company’s Interim Chief Executive Officer and Interim Chief Financial Officer.
Onconetix, Inc. filed a Form 8-K reporting a material event: the filing includes a License Agreement dated September 17, 2025 between Immunovia AB and Proteomedix AG, and an attached Press Release dated September 22, 2025. The 8-K cover page shows standard solicitation/communication checkboxes left unchecked and identifies Karina M. Fedasz as Interim Chief Executive Officer and Interim Chief Financial Officer signing the filing.
This filing discloses the existence and filing of the license agreement and press release but does not include the license terms, financial consideration, milestones, or other commercial details. Investors should note the counterparties and dates disclosed; the filing itself provides notice of the agreement rather than substantive commercial or financial metrics.
Onconetix, Inc. filed a Form 8-K reporting a material event: the filing includes a License Agreement dated September 17, 2025 between Immunovia AB and Proteomedix AG, and an attached Press Release dated September 22, 2025. The 8-K cover page shows standard solicitation/communication checkboxes left unchecked and identifies Karina M. Fedasz as Interim Chief Executive Officer and Interim Chief Financial Officer signing the filing.
This filing discloses the existence and filing of the license agreement and press release but does not include the license terms, financial consideration, milestones, or other commercial details. Investors should note the counterparties and dates disclosed; the filing itself provides notice of the agreement rather than substantive commercial or financial metrics.
Onconetix, Inc. reported a series of waiver agreements with Veru, Inc. extending payment dates for promissory notes multiple times during 2025. The company and Veru executed waivers on March 31, April 23, June 30, July 31 and August 28, 2025, each extending the due dates for the April Veru Note and related Veru Notes, with the most recent extension moving the April Veru Note to September 19, 2025.
The filing also attaches new promissory notes dated August 28, 2025 with Keystone Capital Partners, LLC and KCP Fund I, LLC, plus a Second Amended and Restated Promissory Note and an August 28, 2025 waiver between Veru and the company as exhibits. The disclosures reference earlier forbearance and note documents filed in 2023 and 2024 for full terms.
Andrew Oakley, a non-employee director of Onconetix, Inc. (ONCO), reported changes to his restricted stock awards. A restricted stock award originally granted March 23, 2025 was modified on August 15, 2025 to change the vesting date from August 31, 2025 to August 31, 2026, contingent on continued service as a non-employee director. The filing shows an additional restricted stock award of 618 shares granted that vests August 31, 2026 under the issuer's 2022 Equity Incentive Plan. The amounts are presented on a post 1-for-85 reverse split basis effected June 13, 2025, and total beneficial ownership following the transactions is 638 shares.
Tarsh Simon, a non-employee director of Onconetix, Inc. (ONCO), reported changes to his restricted stock awards. An original restricted stock award granted September 26, 2024 was modified on August 15, 2025 to extend its vesting date from August 31, 2025 to August 31, 2026, conditional on continued service as a non-employee director. The issuer completed a 1-for-85 reverse stock split on June 13, 2025; all share amounts in this report are presented on a post-split basis. The reporting person was also granted a separate restricted stock award of 618 shares that will vest in full on August 31, 2026 if he continues to serve as a non-employee director. The Form 4 is signed by Simon Tarsh on August 19, 2025.
Thomas Meier, a director of Onconetix, Inc. (ticker: ONCO), reported changes to his restricted stock holdings on Form 4 dated 08/15/2025. The filing shows a modification of a previously granted restricted stock award (originally granted 09/26/2024) that changes the vesting date from August 31, 2025 to August 31, 2026, conditioned on continued service as a non-employee director through that date. The filing also reports a restricted stock award of 618 shares that will vest in full on August 31, 2026, and a reported amount of 39 shares related to the modified award, with 657 shares shown as beneficially owned following the transactions (amounts presented on a post 1-for-85 reverse split basis).
The filing discloses the issuer effected a 1-for-85 reverse split on June 13, 2025 and states all share amounts are post-split. No cash consideration is reported for the awards.
Onconetix, Inc. (ONCO) Form 4 filing reports changes to director Timothy Ramdeen's restricted stock awards. The filing shows the Original Award granted 9/26/2024 had its vesting date changed on 08/15/2025 from vesting in full on 08/31/2025 to vesting in full on 08/31/2026, contingent on continued service as a non-employee director. The issuer effected a 1-for-85 reverse stock split on 06/13/2025 and all amounts are shown post-split. The filing also reports a separate restricted stock award of 618 shares that will vest in full on 08/31/2026, subject to continued service. Reported transactions on 08/15/2025 include acquisitions and a disposition, with 658 shares shown as beneficially owned following the transactions.
Onconetix, a commercial-stage biotech that acquired Proteomedix and ENTADFI, reported sharply lower revenue and continuing losses for the quarter ended June 30, 2025. Revenue was $106,494 in the quarter (down from $704,848 a year earlier) and $208,124 for the six months (versus $1,405,281). The company recorded a quarterly net loss of $(2,372,442) and a six-month net loss of $(10,918,327), which included significant goodwill impairment charges (approximately $594,000 for the quarter and $11,512,000 for six months).
Balance-sheet and liquidity pressures are prominent: total assets fell to $19.12 million, goodwill to $18.12 million, cash was $283,515 at June 30, 2025 (approximately $0.2 million as of August 13, 2025), and the company used ~$3.41 million of operating cash in the first half of 2025. Management discloses a working capital deficit of ~$11.8 million and substantial doubt about the company’s ability to continue as a going concern without additional financing or use of the ELOC (approximately $17.0 million available as of August 13, 2025). Near-term debt obligations include Veru notes with principal payments due in August 2025.